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Abstract: Minimal plasmids play an essential role in many intermediate steps in molecular 
biology. They can for example be used to assemble building blocks in synthetic biology or be used 
as intermediate cloning plasmids that are ideal for PCR-based mutagenesis methods. A small 
backbone also opens up for additional unique restriction enzyme cloning sites. Here we describe 
the generation of pICOz, a 1185 bp fully functional high-copy cloning plasmid with an extended 
multiple cloning site (MCS). To our knowledge, this is the smallest high-copy cloning vector ever 
described. 
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1. Introduction 
Minimal plasmids have many uses and can either be generated synthetically [1] or by iterative 
deletions in an existing plasmid. The pUC family [2,3] of plasmids have been extensively used as 
backbone for various cloning and expression vectors [4]. One of the most attractive features of the 
pUC family of plasmids is that they harbor a mutated pMB1 origin of replication (Ori) which leads 
to very high-copy replication of the plasmid [5]. Minimalism is an artistic as well as a functional 
design ideal [6], which provides enhanced robustness and utility in many fields of engineering 
(often referred to as the KISS principle, an acronym with many different interpretations but with 
the same essential meaning : keep it small and simple). The ideal is often summarized by  a quote 
from the French poet Antoine de Saint Exupéry [7]: “It seems that perfection is attained not when there 
is nothing more to add, but when there is nothing more to remove”. In the software world, useless code 
and functions are often referred to as “bloat”, and some software projects have simplicity and 
minimalism as core values in their development philosophy [8] (for example: 
https://suckless.org/philosophy/). Just like in software, useless and bloated code in plasmids can 
cause “bugs”, like the unintended eukaryotic transcription factor binding sites present in the pUC 
plasmids [9,10]. We have thus applied the minimalistic philosophy in the design of a high-copy 
cloning plasmid backbone with as little bloat as possible, which opens up for many improved 
downstream applications. Minivectors have for example been found to be highly efficient for 
mammalian cell transfection [11] and in vivo for gene therapy [12]. Tiny plasmids are however not 
only found in a laboratory settings, replicating minimal plasmids down to 746 bp have also been 
found in nature [13]. There may thus be further room for improvement, which we invite the 
research community to explore further in an open, distributed manner. 
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2. Materials and Methods 
2.1. Iterative deletions of pUC18 
The plasmid was reduced in size in several different reaction (Rxn) steps by PCR as outlined in 
Table 1. Primers were ordered from Invitrogen. The in silico cloning, graphical vector map 
generation and sequence analyses was done in UGENE (http://ugene.net/) [14].  
Table 1. Overview of primers used in the iterative shrinking of pUC18 into pICOz. 
Primer name Sequence 
PCR 
rxn 
PUC18-dLacZ-F gccgttaacccatggccaagcttgcatgcctgcaggtcg 1 1 
pUC18-dLacZ-R ccatatggcctcgcgacgcgttatgtatccgctcatgag 1 1 
pUCmini-F gtgggcccgtttaaacacatgtgagcaaaaggccag 2 1 
PUCmini-R tagtctcgaggatatccgaattcgagctcggtac 2 1 
pUCmu-F taccaatgcttaatcagtgaggca 3 1 
pUCmu-R agtagaaaagatcaaaggatcttct 3 1 
pUcReFix-F attagctcgagactagtgggcccgtttaaacacatgtgtttttccataggctccg 4 2 
pUcReFix-R ctaatctcgaggatatccgaattcgagctcggtacccgggatcctctagagtcgacctg 4 2 
pICOz-dAMP-F ttcgtggccgaggagcaggactgacgtagaaaagatcaaaggatctt 5 3 
pICOz-dAMP-R aacggcactggtcaacttggccatactcttcctttttcaatattat 5 3 
PICOz-Zeo-F ataatattgaaaaaggaagagtatggccaagttgaccagtgccgtt 6 3 
pICOz-Zeo-R aagatcctttgatcttttctacgtcagtcctgctcctcggccacgaa 6 3 
1 Phusion DNA polymerase PCR, phosphorylated primers + T4 ligation. 2 Phusion DNA polymerase PCR, 
digestion + T4 ligation. 3  Universe DNA polymerase PCR, CloneEZ recombination. 
Phusion DNA polymerase (New England Biolabs) PCR reactions were performed with the 
following general program: 3 min 98 oC denaturation, 35x [10 s 98 oC denaturation, 20 s 57 oC 
annealing, 20 s/kbp 72 oC elongation], 10 min 72 oC. The Universe DNA polymerase (Biotool) PCR 
progam was 5 min 95oC denaturation, 35x [20 s 95 oC denaturation, 20 s 57 oC annealing, 45 s/kbp 72 
oC elongation], 10min 72 oC elongation on a GeneAmp 9700 (PE Biosystems) thermocycler. Ligation 
with T4 DNA ligase (Promega) was performed at room temperature over night. CloneEZ 
(GenScript) reactions were performed for 30 minutes at room temperature. All DNA products were 
transformed into competent MC1061 E. coli by 30 s heat shock at 42 oC. 
2.2. Verification, storage and distribution of DNA material 
The resulting plasmids were deposited to the ISO 9001:2008 [15] compliant BCCM/GeneCorner 
culture collection (www.genecorner.ugent.be) under the following accession numbers for re-
distribution: pUC18deltaLacZ (LMBP 9213), pUCmini (LMBP 9221), pUCmu (LMBP 9329) and 
pICOz (LMBP 11103). All plasmids were verified by Sanger sequencing (internal sequencing 
facility) and restriction enzyme digestion (Promega).  Genbankfiles for pUCmu and pICOz in 
supplemental data. 
 
2.3. Determination of relative yield of plasmid variants 
The plasmids pUC18, pUC18deltaLacZ, pUCmu and pICOz were grown in quadruplicates and 
plasmids were prepped from 3 ml culture per plasmid and replicate using HQ Mini Plasmid 
Purification Kit (Invitrogen). DNA concentrations were determined by NanoDrop ND-8000 
(ThermoFisher). 
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3. Results 
3.1. Generation of a minimal cloning plasmid with an extended multiple cloning site 
In order to shrink a high-copy and widely used cloning backbone like pUC18, we sequentially 
eliminated code segments that we identified as “useless bloat”. The first reaction (Rxn1; Figure 1) 
eliminated LacZ and some additional sequence upstream of the pBla promoter driving Ampicilin 
resistance. The eliminated sequence got replaced by some additional restriction enzyme sites (MluI, 
NruI, SfiI, NdeI, NcoI, MscI; Figure 2) that were added to the multiple cloning site (MCS). This 
resulted in  pUC18deltaLacZ, which is 496 bp smaller than the pUC18 parental plasmid. 
 
 
Figure 1. Overview of the cloning scheme for generation of a minimal vector backbone. (a) 
Graphical overview of the modifications made in each step in the miniaturization process. Rxn = 
reaction. Red lines indicate area that was modified in the following reaction.; Green plasmid 
elements indicate the annotated Ori in the plasmid; Grey plasmid elements are “useless” annotated 
elements; Blue plasmid elements indicate antibiotic selection marker; Red plasmid elements indicate 
annotated prokaryotic transcription terminators. (b) XbaI digest of 3µg pUC18, ΔlacZ 
(=pUC18deltaLacZ), pUCmu and pICOz run on a 1% Agarose/TAE gel. Sizes on the SmartLadder 
(Eurogentec) indicated in kbp (“k”). 
In the second reaction (Rxn2, Figure 1), we eliminated additional parts of the LacZ promoter 
and useless code between the MCS and the origin of replication (Ori) from  pUC18ΔLacZ, and this 
code got replaced by additional restriction enzyme sites in the MCS (EcoRV, XhoI, SpeI, ApaI, PmeI 
; Figure 2). By random chance, a clone that was picked up showed a deletion in the pUC Ori and 
part of the MCS without showing any detrimental effects on plasmid yield. This plasmid was kept 
as pUCmini, which is 432 bp smaller than the  pUC18deltaLacZ parental plasmid. 
In order to shrink the plasmid further, an additional region with useless code was identified 
between the ampicillin resistance and the Ori, and a deletion was made to make the resistance 
marker use a terminator sequence present in the Ori (Rxn 3, Figure 1). Since the pUCmini plasmid 
also had a deletion in the MCS, we also repaired the MCS to restore the lost restriction enzyme sites 
(Rxn 4, Figure 1). The resulting pUCmu plasmid ended up being 89 bp smaller than pUCmini but 
with a complete extended MCS. 
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Figure 2. Comparisons of the original pUC18 MCS compared to the extended MCS in pUCmu and 
pICOz. Restriction sites are indicated in alternating red and black text for clarity. Overlapping 
nucleotides for two restriction sites are indicated in purple. 
 
After this reaction, no “useless bloat” code could be identified in the sequence and the only 
way to further shrink the plasmid was by replacing the antibiotic selection with a smaller selectable 
marker using overlap extension cloning [16] or recombination-based cloning. As a proof-of-concept, 
we replaced ampicillin resistance with zeocin resistance by amplifying the pUCmu plasmid without 
the ampicillin resistance sequence (Rxn 5, Figure 1) and recombined this PCR product with a PCR-
amplified zeocin resistance gene (Rxn 6) using CloneEZ. In parallel, a PCR-based fusion between 
the two fragment was equally successful. The resulting pICOz plasmid is 484 bp smaller than the 
minimal pUCmu parental plasmid. 
With these four sequential steps of elimination, we have thus been able to reduce the 2686 bp 
pUC18 plasmid to the 1185 bp pICOz plasmid which contains more useable cloning sites, a total 
size reduction of 56%. 
 
3.2. Determination of absolute and relative yield of the minimal cloning plasmids 
In order to verify that the deletions had not eliminated anything that would impact plasmid 
copy number and total yield, we did several parallel heat shock E. coli transfections and mini 
plasmid preparations of four constructs (pUC18, pUC18deltaLacZ, pUCmu and pICOz). 
 
 
Figure 3. (a) Absolute yield (µg/ml over night culture) for the four constructs. (b) Plasmid size-
adjusted relative yield (average pUC18 yield set to 1) and divided by relative size (pUC18 = 1, 
pUC18deltaLacZ = 0.81, pUCmu = 0.62 and pICOz = 0.44). The plasmid size-adjusted yield should 
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be correlated with number of plasmid molecules extracted/ml of over night culture. Error bars 
represent 95% confidence intervals (Student’s t distribution [17]). 
Surprisingly, pUCmu shows a very high yield both in absolute amount of DNA produced 
from an over night culture (Figure 3a) and even more so when factoring in that this plasmid is 
much smaller than the pUC18 parental plasmid (Figure 3b). This yield gain in pUCmu is lost in 
pICOz, possibly because of less efficient growth of the bacteria under Zeocin selection in low-salt 
LB medium. The pICOz plasmid does however still out-perform pUC18 both in absolute yield and 
plasmid size-adjusted relative yield (Figure 3b). 
 
 
4. Discussion 
4.1. Generation of a minimal cloning plasmid – how small can we go? 
We here describe the generation of a minimal ~1kb fully functional cloning plasmid, which is 
as far as we currently can get in miniaturization. All useless sequences have been eliminated and 
there is no additional space between the MCS, Ori and selectable marker (Fig. 1). We now use the 
smallest widely used resistance marker and the only way to shrink the plasmid further is to do 
additional deletion/engineering of the Ori or replace the Ori with an alternative, smaller, Ori. By 
lucky coincidence, we managed to identify a random deletion mutant of the pUC variant of the 
pMB1 Ori, which shrunk the pUC Ori from 750 bp to 616 bp. A minimal pUC-derived Ori of 674 bp 
(GenBank: EU496091.1) has been described in the BioBrick system [18]. Sequence comparisons 
reveal alignment between pICOz and base 3-618 of the BioBrick pUC Ori. The alignment also 
revealed that the BioBrick pUC contains a few point mutations to eliminate restriction sites in the 
Ori. Our minimal backbone could in principle very easily be made completely synthetically, where 
all restriction sites in the backbone in theory could be eliminated and the MCS be further extended. 
This could be one very interesting future prospect for further development of the pICOz backbone 
as a standard IGEM ( http://igem.org/ ) “part” for synthetic biology [19,20]. Our random deletion 
pUC Ori mutant is likely to be the most minimal variant of the pUC Ori that can be generated, since 
RNAII (27-615 bp on the BioBrick genbank annotation) is absolutely needed. A minimal Ori from 
pSC101 of only 220 bp has been described [21], but this is a low copy plasmid which usually is less 
interesting and it is not entirely clear if this minimal element is sufficient to make a self-replicating 
plasmid. For example the pMB1/pUC Ori often annotaded in the pUC plasmid maps is not the 
complete sequence required for plasmid replication (Figure 1). In theory, however, it should be 
possible to shrink pICOz to 789 bp with this minimal Ori if it works. With our 1185 bp, we are 
however already very close to the absolutely smallest plasmid ever found in nature (746 bp), and 
we usually need a high-copy plasmid and a selectable marker to have a useful cloning vector, 
which currently restricts further size optimization. The selectable marker unconditionally adds at 
least 458 bp (promoter+coding domain sequence (CDS)+terminator), so it might be that we are 
already at the lowest limits of what can be obtained for a fully functional high-copy cloning vector 
in E. coli. 
  
4.2. Practical use-cases of a small cloning plasmid 
There are several potential use-cases for a tiny plasmid backbone. One very useful use-case is 
for example to use pICOz as an intermediate cloning plasmid for PCR-mediated mutagenesis and 
then clone the generated mutant into the expression vector. This has three major advantages: 1) The 
PCR only needs to amplify a small product (insert + 1 kb) rather than the entire expression vector 
(typically insert + 5-6 kb for mammalian expression vectors), 2) there is no risk that the PCR 
amplification has caused any unintended modifications to the expression vector and 3) since most 
expression vectors are ampicillin resistant, cloning from the zeocin-resistant intermediate pICOz 
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 15 October 2018                   doi:10.20944/preprints201807.0287.v2
 6 of 9 
vector reduces the risk of contamination from the parental pICOz vector and ligation into the 
expression vector can be done even without purification of the digest. 
The pICOz and pUCmu vector backbones can also be interesting as expression vector 
backbones in some cases. However, adding a complete mammalian expression casette and SV40 
origin of replication defeats the purpose of the tiny backbone since the few kb saved on the 
backbone will make little difference on the final size of the expression vector. There are however 
use cases with much smaller expression casettes, like for example CRISPR/Cas9 guideRNA 
expression from the U6 promoter and terminator (for example: pU6mu LMBP 09491 and pU6z 
LMBP 11144). Expression of these guide RNAs are also preferably transient, so we do not need the 
SV40 origin of replication. We have experienced that some cells are more easily transfected with 
small expression plasmids (for example, electroporation of Jurkat T cells), which means that these 
small expression plasmids can have a practical use case. 
There are however many more potential use cases of these small vector back bones in many 
fields of molecular biology and we encourage creative use of this tool to develop novel downstream 
applications. 
4.3. Future distributed development and the importance of sharing 
We highly encourage others to try to further improve on our best attempt to generate a 
minimal core cloning plasmid. Distributed development has been shown to be an extremely 
powerful force in open source software development [22], and genetic material shows many 
commonalities with software in that it can be copied and reproduced very easily [23]. An essential 
component for a functional distributed development of genetic material is the availability of reliable 
repositories of verified material to be distributed with as few restrictions as possible [24,25]. For 
plasmids, this means culture collections like Addgene (www.addgene.org) and BCCM/GeneCorner 
(www.genecorner.ugent.be). One potential uncertainty in plasmid development and other genetic 
resources is still the intellectual property status of derived material [26–28], which sometimes is 
covered by a Materials Transfer Agreement (MTA) but not always. A true copyleft for genetic 
material does not exist, but there are some efforts to bring this very successful cultural and legal 
philosophy from open source software also to the development of genetic material [29–31]. 
People developing this backbone further are naturally free to explore and adapt it in any way 
they see fit. Interesting future perspectives would however be to further explore alternative Ori and 
selectable markers in this vector backbone to try to shrink it further. Also extending the MCS and 
making a synthetic “un-cleavable” pICOz backbone is a very interesting idea for future 
development. Also other optimization aspects than size and cloning properties can however be 
interesting. For example, non-antibiotic selectable markers (like Zn2+ [32], Cu2+ [33], Ag+ [34] or high-
salt [35] resistance) could be highly interesting to explore for E. coli cloning vectors. 
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